AI
ADAP

Acuitas Investments’s Adaptimmune Therapeutics ADAP Stock Holding History

Acuitas Investments’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-541,201
Closed -$528K – 118
2024
Q2 		$528K Buy
541,201
+2,880
+0.5% +$3.16K 0.28% 96
2024
Q1 		$851K Buy
538,321
+58,532
+12% +$70.7K 0.43% 73
2023
Q4 		$380K Buy
479,789
+25
+0% +$14 0.2% 107
2023
Q3 		$374K Buy
+479,764
New +$403K 0.22% 95

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acuitas Investments's ADAP Position: Q3 2024 in Review

Acuitas Investments sold out of Adaptimmune Therapeutics (ADAP) in Q3 2024, closing a stake of 541,201 shares — an estimated $528K sold.

Acuitas Investments first reported a position in ADAP in Q3 2023 and held it in 4 quarters. The position peaked at $851K in Q1 2024. 81 funds tracked by Wall St. Rank hold ADAP as of Q3 2024.

  • Acuitas Investments reported no remaining Adaptimmune Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Acuitas Investments sold 541,201 Adaptimmune Therapeutics shares in Q3 2024, an estimated $528K.
  • Acuitas Investments first reported a position in Adaptimmune Therapeutics in Q3 2023 and held it in 4 quarters.
  • Acuitas Investments's Adaptimmune Therapeutics position peaked at $851K in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2024.

Based on Acuitas Investments's 13F filing for Q3 2024, filed 7 Nov 2024.